Research Analysts Offer Predictions for RIGL Q1 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Rigel Pharmaceuticals in a note issued to investors on Wednesday, March 5th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.07) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $57.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' Q2 2025 earnings at $0.12 EPS, FY2025 earnings at $0.88 EPS and FY2026 earnings at $2.08 EPS.

Other equities analysts have also issued research reports about the company. Piper Sandler raised their price target on Rigel Pharmaceuticals from $15.00 to $23.00 and gave the company a "neutral" rating in a research note on Thursday, November 14th. StockNews.com downgraded shares of Rigel Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday. B. Riley boosted their price target on shares of Rigel Pharmaceuticals from $20.00 to $24.00 and gave the company a "neutral" rating in a report on Wednesday, March 5th. Citigroup increased their price objective on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Finally, Cantor Fitzgerald boosted their price objective on shares of Rigel Pharmaceuticals from $15.00 to $25.00 and gave the stock a "neutral" rating in a research note on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $36.80.

Remove Ads

Rigel Pharmaceuticals Stock Performance

RIGL traded down $0.04 during trading on Friday, hitting $19.49. 288,194 shares of the stock were exchanged, compared to its average volume of 247,376. Rigel Pharmaceuticals has a 1 year low of $7.48 and a 1 year high of $29.82. The firm has a market cap of $348.15 million, a price-to-earnings ratio of 139.22 and a beta of 1.35. The firm has a 50 day simple moving average of $20.28 and a 200 day simple moving average of $18.62.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last issued its earnings results on Tuesday, March 4th. The biotechnology company reported $0.80 EPS for the quarter, topping analysts' consensus estimates of $0.30 by $0.50. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. The business had revenue of $57.60 million for the quarter, compared to the consensus estimate of $57.59 million.

Insider Transactions at Rigel Pharmaceuticals

In other Rigel Pharmaceuticals news, CEO Raul R. Rodriguez sold 4,952 shares of Rigel Pharmaceuticals stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total value of $103,595.84. Following the transaction, the chief executive officer now directly owns 243,854 shares of the company's stock, valued at approximately $5,101,425.68. The trade was a 1.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dean L. Schorno sold 2,036 shares of the company's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total value of $42,593.12. Following the transaction, the chief financial officer now directly owns 58,969 shares in the company, valued at approximately $1,233,631.48. The trade was a 3.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,113 shares of company stock valued at $190,644 in the last 90 days. Insiders own 9.04% of the company's stock.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Rigel Pharmaceuticals in the 4th quarter valued at approximately $63,000. Wells Fargo & Company MN raised its holdings in shares of Rigel Pharmaceuticals by 44.5% in the fourth quarter. Wells Fargo & Company MN now owns 8,603 shares of the biotechnology company's stock worth $145,000 after buying an additional 2,648 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Rigel Pharmaceuticals by 42.8% during the fourth quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company's stock worth $159,000 after buying an additional 2,827 shares during the period. Graham Capital Management L.P. purchased a new stake in shares of Rigel Pharmaceuticals during the fourth quarter valued at $170,000. Finally, Integrated Quantitative Investments LLC acquired a new position in shares of Rigel Pharmaceuticals in the 4th quarter valued at $181,000. Hedge funds and other institutional investors own 66.23% of the company's stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.